Compugen Ltd. (NasdaqCM: CGEN)
Health Care · Biotechnology · IL
$2.87
+9.75% today · +80.3% 1Y
Compugen Ltd. (NasdaqCM: CGEN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $247.70M and employs 75 people.
Over the last twelve months the share price has gained 80.3%, trading between 1.30 and 3.24.
Tweenvest scores Compugen Ltd. across four factors: quality 50/100, value 28/100, growth 100/100. Its strongest factor is growth.
CGEN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $247.70M
- Revenue (TTM)
- $74.00M
- P/E
- 7.00
- EPS
- 0.37
- Dividend yield
- —
- Beta (5Y)
- 2.78
- 52-week high
- $3.24
- 52-week low
- $1.30
- Avg volume (3M)
- —
- Shares outstanding
- 94.72M
- Employees
- 75
- Next earnings
- —
About Compugen Ltd.
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.
- ISIN
- IL0010852080
- Founded
- 1993
- Listed since
- Aug 11, 2000
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.